<?xml version="1.0" encoding="UTF-8"?>
<p id="p0220">A phase III clinical trial (ACTRN12619000764134) is ongoing to assess the safety and efficacy of povidone-iodine nasal spray (NasodineÂ®) in the treatment of subjects affected by common cold, potentially caused by human coronaviruses (
 <xref rid="bib24" ref-type="bibr">Firebrick Pharma Pty Ltd., 1261</xref>). PVP-I awaits clinical trial data confirming an effective activity of drug against SARS-CoV-2.
</p>
